Description
STEM CELLS IN REGENERATIVE MEDICINE: CARPE DIEM – CARPE VITAM
(ISBN 978-1-83859-011-6)
It also highlights important aspects of manufacturing and culturing of cell therapy products and administration of different types of stem cells in various systemic disorders.
Mike K.S. Chan & Dmitry Klokol
ISBN 978 1838590 116
Table of Content
Foreword | xv |
Introduction | xix |
PART 1 | 1 |
Chapter 1 | 3 |
UNDERSTANDING STEM CELLS | 3 |
From Embryology to Regenerative medicine | 3 |
History of stem cell research | 6 |
Stem cell biology | 15 |
Choice of Stem Cells in Wellness and Biological medicine | 29 |
Chapter 2 | 33 |
PREPARATION, STANDARTIZATION, LABORATORY ANIMAL CARE, SAFETY PROTOCOLS, AND REGULATORY ASPECTS OF STEM CELLS, XENOTRANSPLANTS, AND BIOMOLECULAR THERAPY PRODUCTS | 33 |
Animal sources of stem cell xenotransplants | 36 |
Tissue procurement and cell culturing | 41 |
Archiving of medical records and specimens from animal source | 44 |
Quality control | 45 |
Release and labelling of precursor stem cells | 47 |
Chapter 3 | 51 |
GENETIC AND IMMUNOLOGICAL ASPECTS OF CELLULAR XENOTRANSPLANTATION | 51 |
Genotype-phenotype distinction and relationships between donor cells and recipient | 52 |
Epigenetics and Stem cells | 57 |
Immunology and genetics in Stem cell therapy | 61 |
Chapter 4 | 83 |
SAFETY CONSIDERATIONS OF FETAL XENOGENEIC PRECURSOR STEM CELLS | 83 |
Chapter 5 | 109 |
STEM CELLS’ BIOCHEMICAL BASIS AND MECHANISMS OF ACTION | 109 |
Homing and migration of fetal precursor stem cells | 110 |
Adhesion, binding and interaction of fetal precursor stem cells | 112 |
Paracrine mechanisms of fetal precursor stem cells | 115 |
Soluble paracrine factors of fetal precursor stem cells | 117 |
Insoluble paracrine factors of fetal precursor stem cells | 118 |
Further considerations on immunogenicity of Fetal Precursor Stem Cells | 122 |
Chapter 6 | 122 |
AUTOLOGOUS STEM CELLS AND ITS THERAPEUTIC POTENTIAL | 127 |
Autologous stem cells and history of its transplantation | 128 |
Autologous Stem Cell Transplantation | 132 |
Very small embryonic stem cells (VSELs) | 136 |
Clinical applications of Autologous SC transplantation in different diseases | 147 |
PART 2 | 169 |
Chapter 7 | 171 |
MORPHO-PHYSIOLOGIC BACKGROUND AND SUBSTANTIATION OF PRECURSOR STEM CELL THERAPY USE IN NEURODEGENERATIVE DISEASES | 171 |
Chapter 8 | 185 |
CELL THERAPY IN MANAGEMENT OF AUTISM SPECTRUM DISORDERS | 185 |
Outlook on the etiology and pathogenesis of ASD. Role of genetics and immunity in development of Autism and ASD | 186 |
Role of imaging studies and biological markers in Autism and ASD and its links to symptomatology | 188 |
Integrative therapeutic protocol for Autism and ASD | 191 |
Chapter 9 | 203 |
CELL THERAPY IN MANAGEMENT OF AUTISM SPECTRUM DISORDERS | 203 |
Social and general medical aspects of AD | 203 |
Therapeutic strategies in AD | 218 |
Stem cell therapy in treatment of AD | 225 |
Mito Organelles™ CNS Neuropeptides in management of AD | 228 |
Chapter 10 | 233 |
CELL THERAPY IN PARKINSON’S DISEASE | 233 |
Social and general medical aspects PD | 233 |
Protective factors against PD | 240 |
The role of mitochondria in PD | 243 |
Clinical forms of PD | 246 |
Clinical diagnosis of PD | 252 |
Treatment strategies in PD | 253 |
Treatment of Parkinson’s disease with precursor stem cells | 257 |
Neuropeptides Mito Organelles™ CNS in management of PD | 265 |
Transcranial electric and magnetic stimulation of the brain (TCS) | 266 |
Chapter 11 | 271 |
CELL THERAPY IN STROKE MANAGEMENT | 271 |
Social and general medical aspects of stroke | 271 |
Risk factors and symptoms of stroke | 277 |
Post-stroke rehabilitation | 286 |
Stem cells and cell therapy in management of stroke | 292 |
MO CNS neuropeptides in management of stroke patients | 297 |
PART 3 | 303 |
Chapter 12 | 305 |
CELL THERAPY IN MANAGEMENT OF DIABETES MELLITUS | 305 |
Morpho-physiology of pancreas and general medical aspects of diabetes mellitus | 305 |
Stem cells and live cell therapeutic approach in management of diabetic patients | 323 |
Chapter 13 | 335 |
CELL THERAPY IN MANAGEMENT OF CARDIOMYOPATHY | 335 |
Pathogenesis of cardiomyopathies and cardiac regenerative potentials | 335 |
Cell therapy as treatment modality in cardiomyopathy | 359 |
Chapter 14 | 371 |
CELL THERAPY IN MANAGEMENT OF CHRONIC KIDNEY DISEASE | 371 |
Mechanisms of kidney regeneration | 372 |
Stem cells in kidney’s regeneration | 372 |
Stem cells xenotransplantation in management of CKD | 377 |
Chapter 15 | 389 |
CELL THERAPY IN MANAGEMENT OF LIVER DISEASE | 389 |
Pathogenesis of liver disease | 389 |
Cell therapy based treatment of liver disease | 402 |
Chapter 16 | 421 |
CELL THERAPY IN TREATMENT OF MUSCULAR DYSTROPHIES | 421 |
General medical considerations on muscular dystrophies | 421 |
Pathogenesis and diagnostics of Muscular Dystrophy | 424 |
Novel treatment strategies in Muscular Dystrophy | 428 |
Chapter 17 | 439 |
CELL THERAPY IN MANAGEMENT OF RETINOPATHY | 439 |
Retina’s morphology and pathogenesis of retinopathies | 439 |
General considerations of cell therapy based treatment strategies in retinopathy | 445 |
Bioengineering in Clinical Trials using Human Pluripotent Stem Cells | 446 |
Precursor Stem Cell/ Live Cell Therapy in Retinal Diseases | 452 |
Cell-based therapies for retinal pigment epithelium replacement | 468 |
Cell-based therapies for photoreceptor replacement | 471 |
Chapter 18 | 475 |
PLACENTAL THERAPY AS PART OF CELL THERAPY AND REGENERATIVE MEDICINE | 475 |
Morphophysiology of placenta and physiological background of placental therapy | 475 |
Main characteristics of placental therapy products | 479 |
Biological and medicinal properties of placental extracts | 483 |
Placental therapy in treatment of hair loss | 486 |